Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Hepatology CommunicationsOpen Access

Pathological study of the tumor microenvironment after neoadjuvant therapy in hepatocellular carcinoma: Difference of TACE combined with antiangiogenics and immunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

XHXintao HeNanjing University of Chinese MedicineYLYanhong LiuHebei Medical UniversityTDTianyi Dai

Discussion

Loading...

Member takes

Implication

Retrospective analysis highlights enhanced disease-free survival in patients treated with TACE combined with immunotherapy and antiangiogenic therapy.

Key Points

  • Elevated disease-free survival rates were observed in the TACE combined with immunotherapy group compared to TACE alone.
  • CD8+ tumor-infiltrating lymphocytes were identified as a key prognostic factor for neoadjuvant treatment in HCC.
  • Differences in immune cell infiltration and vascular classification were significant between treatment groups, impacting treatment efficacy.
  • Presence of VETC and carbonic anhydrase 9 were associated with treatment outcomes, suggesting their potential as efficacy indicators.

Cite This Study

He et al. (2025) studied this question.

synapsesocial.com/papers/68c243acb210217d647a76fbhttps://doi.org/10.1097/hc9.0000000000000787
View Full Paper
Ask AI
Bookmark
Share